CVRx reports preliminary Q1 2026 revenue $14.7-14.8M, +20% YoY; gross margin 87%

CVRx, Inc.

2026-Q1 EPS reported -$0.50 vs consensus -$0.51 ▲ beat (+2.8%)

Revenue expected $14.7-14.8M vs $12.3M in Q1 2025, ~20% growth.
Gross margin ~87% (84% in Q1 2025); operating expenses ~$25M vs $23.7M.
Cash and equivalents ~$72.3M at Mar 31, 2026; active implanting centers 257 (+5 vs Dec 2025).
Medicare Advantage 30-day approval rate rose to 50% in Jan-Feb 2026 vs 44% in 2025 and 31% in 2024.
First site activated in BENEFIT-HF trial on Mar 31; enrollment expected Q2 2026.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVRx, Inc. reported first quarter ended March 31, 2026 results: revenue $14.7 million to $14.8 million.

Period: first quarter ended March 31, 2026
Revenue: $14.7 million to $14.8 million
Result: preliminary results

Exact text from the filing

EXHIBIT 99.1 Exhibit 99.1 CVRx Reports Preliminary First Quarter 2026 Financial Results · Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 · Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

CVRx, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-042354

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.